One notable target is cyclin-dependent kinase 12 (CDK12), whose inhibition has demonstrated efficacy against Leishmania parasites, suggesting its potential as a therapeutic target for visceral leishmaniasis (Wyllie et al., 2018). The gene discussed is CDK12; the disease is visceral leishmaniasis.